Evidence map›Paper›PMID 31909189›Full record

ArticleBMJ open ophthalmology2019

Defining the needs and preferences of patients with dry eye disease.

Penny Asbell, Elisabeth Messmer, Colin Chan, Gary Johnson, Brigitte Sloesen, Nigel Cook

Open access · goldAbstract read
In one paragraph

Article in BMJ open ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Trends in Dry Eye Disease Management Worldwide.Clinical ophthalmology (Auckland, N.Z.) · 2021
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 5 countries.

Penny AsbellOphthalmology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Elisabeth MessmerDepartment of Ophthalmology, Ludwig Maximilians University, Munich, Germany.
Colin ChanCentral Clinical School, University of Sydney, Sydney Medical School, Sydney, New South Wales, Australia.
Gary JohnsonInpharmation, High Wycombe, UK.
Brigitte SloesenGlobal Patient Access, Novartis Pharma, Basel, Switzerland.
Nigel CookGlobal Patient Access, Novartis Pharma, Basel, Switzerland.ORCID 0000-0001-8211-7613
Novartis (Switzerland) · CHIcahn School of Medicine at Mount Sinai · USLudwig-Maximilians-Universität München · DEMundipharma (United Kingdom) · GBThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDry eye disease is a multifactorial chronic disease, leading to ocular discomfort and visual disturbance with a substantial impact on quality of life. Therefore, the patient's perspective should be taken into account early in the drug development process. We have developed a step-by-step methodology based on the self-explicated conjoint approach to assess the needs and preferences of patients with moderate-to-severe dry eye disease. METHODS AND ANALYSIS: Following a literature review and social media listening (step 0), qualitative phone call interviews were conducted with 12 patients (step 1). Patients' responses underwent content analysis and were coded, quantified and displayed as charts. Based on the emerging trends and attributes identified as relevant in steps 0 and 1, a quantitative online questionnaire was designed and conducted with 160 patients across four countries (step 2).

resultsThe online questionnaire was rated as easy/very easy to understand by 60% of respondents, 62% rated the survey as easy/very easy to complete and 71% rated it as interesting/very interesting. Treatment satisfaction was the most important aspect for patients, and the three most relevant attributes were as follows (with the most important indexed to 100%): 'treatment effectiveness on symptoms of dry eyes' (100%), 'frequency of treatment use' (96%) and 'how the treatment works' (95%).

conclusionOur methodology was well received by patients, and the results will help inform future clinical trial development and discussions with health technology assessment bodies and regulators on unmet needs and product attributes that are of most value to patients with dry eye disease.

Indexed as

ocular surfacepharmacologypublic healthtearstreatment medical

Identifiers

PMID31909189
PMCPMC6936476
OpenAlexW2991715675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.